HY-N1082-25mg
|
MedChemexpress LLC
|
Visnagin [CAS 82-57-5]
|
|
COVID-19-immunoregulation
|
|
HY-N1082-50mg
|
MedChemexpress LLC
|
Visnagin [CAS 82-57-5]
|
|
COVID-19-immunoregulation
|
|
HY-N1082-1mL
|
MedChemexpress LLC
|
Visnagin [CAS 82-57-5] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
HY-123931-10mg
|
MedChemexpress LLC
|
ZLDI-8 [CAS 667880-38-8]
|
|
Cancer-programmed cell death
|
|
HY-123931-100mg
|
MedChemexpress LLC
|
ZLDI-8 [CAS 667880-38-8]
|
|
Cancer-programmed cell death
|
|
HY-123931-5mg
|
MedChemexpress LLC
|
ZLDI-8 [CAS 667880-38-8]
|
|
Cancer-programmed cell death
|
|
HY-123931-50mg
|
MedChemexpress LLC
|
ZLDI-8 [CAS 667880-38-8]
|
|
Cancer-programmed cell death
|
|
HY-123931-1mL
|
MedChemexpress LLC
|
ZLDI-8 [CAS 667880-38-8] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|